The funding will primarily be allocated toward the submission of an application to British regulators to allow for the ...

Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform.

Qnovia, Inc., a pharmaceutical company who recently announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the RespiRx™ Nicotine ...

Qnovia has received clearance from the US Food and Drug Administration (FDA) to start a clinical trial for its RespiRX ...

Qnovia, a Richmond startup focused on smoking-cessation technology, has raised $16 million in a Series B round.

In conclusion, NRT (nicotine gum or inhaler) doubled the quit rate compared ... 46.6 ± 10.0 (20–67) Age started smoking (years) 18.3 ± 3.3 (8–30) 18.6 ± 3.9 (12–42) Cigarettes smoked ...

smoking habits and frequency of GP visits. They found that between seven and 12 prescriptions of reliever inhalers in the previous year increased the risk 16-fold and 13 or more prescriptions ...

Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...

Protect your lungs this winter! Tips for asthma, COPD, & other respiratory conditions. Learn how to stay healthy & avoid ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.